Healthcare AI Solutions: Match the Use Case to the Workflow

Healthcare AI solutions use artificial intelligence to support a defined healthcare task: preparing documentation, drafting messages, analyzing images, finding information or organizing operational work. The useful unit of comparison is the complete workflow—input, output, responsible person and next action—not the model or company name.

A clinic with unfinished notes has a different purchasing problem from a screening service with a reading backlog. Both may consider AI, but they need different evidence, interfaces, staff and safeguards. Even a good prediction or well-written draft can be a poor solution if nobody can use it at the right moment.

This guide helps clinicians, administrators and governance teams decide what to pilot, what to repair first and what to decline. It is not a universal ranking. The healthcare AI companies guide covers suppliers; this page centers on problem selection, acceptance and accountable operation.

Sources last checked October 5, 2026. Vero publishes this article and sells AI documentation software. Lauren Bennett is a Vero contributor; separate clinician and AI-governance review has not been completed. The worked referral, scheduling and cost examples are fictional, not patient records, observed deployments or product test results. The guidance is general implementation information, not patient-specific medical or legal advice.

Start with the problem, not the AI category

Write the problem without using the word AI. For example: “Staff spend too long identifying incomplete referral packets, and some missing documents are discovered only after a clinician opens the appointment.” That statement identifies a workflow and a possible baseline. “We need an AI platform” does neither.

Next, identify why the work is slow. Is someone rewriting information, searching across systems, waiting for permission, correcting inconsistent data or handling exceptions? A drafting model will not fix missing source access. A routing model will not create available appointments. Sometimes the appropriate first change is a better form, a documented queue owner or a reliable interface.

Scroll horizontally to compare the task, output and acceptance measure. Keyboard users can focus the table and use arrow keys.

This map suggests evaluation questions; it does not establish that a named product can perform every task. Predictive models and image analysis are not necessarily generative AI. For text-generation failure tests, use the deeper generative AI implementation guide.

What the evidence supports and what it does not

Useful evidence names the task, comparator, population, configuration and endpoint. Keep three records separate: published findings, vendor-documented capabilities and your local observations. A capability statement establishes what a supplier describes, not the improvement a clinic will obtain.

Documentation: benefit depends on the tested product and endpoint

The 2025 randomized trial by Lukac and colleagues assigned 238 outpatient physicians across 14 specialties to DAX Copilot, Nabla or usual care. Nabla reduced time-in-note by 9.5% versus control; DAX’s −1.7% difference was not statistically significant. The study ran for two months, and each tool was used in roughly a third of its assigned group’s visits. Clinicians reported occasional clinically significant inaccuracies. Original randomized scribe trial.

This supports evaluating documentation tools in practice, not promising a universal saving. It did not test Vero. Time-in-note is also not equivalent to total clinic labor or improved patient outcomes. Our implementation inference is to measure review, transfer and exception work alongside writing time.

Messaging: a draft can add reading work

Tai-Seale and colleagues’ 2024 randomized waiting-list quality-improvement study involved 52 participating physicians and 70 contemporary controls at an academic health system. AI-assisted replies were associated with 21.8% longer read time, no statistically significant change in reply time and longer responses. Original message-drafting study.

A compassionate starting point can still be useful, but “generates a reply” does not answer “reduces inbox effort.” The result concerns that implementation and observation period, not every current messaging model. A local comparison should include an approved template as well as manual drafting, and assess whether the patient’s actual request is resolved.

Screening: evaluate the clinical pathway, not a generic accuracy score

The 2026 MASAI report studied 105,934 women randomized in Swedish mammography screening; 19 were excluded from analysis. AI-supported reading was compared with standard double radiologist reading. Interval cancer rates were 1.55 versus 1.76 per 1,000 participants, a ratio of 0.88 (95% CI 0.65–1.18). The trial met its non-inferiority criterion; this was not a statistically significant reduction in interval cancers. Original MASAI screening trial.

The studied reading pathway retained radiologists. It is not evidence for an autonomous chatbot, every imaging product or a mortality benefit. For an imaging purchase, the appropriate clinical team must examine the exact intended population, equipment, reading protocol and follow-up—not borrow documentation metrics.

Solution fit: inputs, delivery and permitted actions

Before a demonstration, ask the supplier to complete a one-page fit statement. Specify the exact offering and plan; input sources; required hardware or interfaces; output destination; geographic availability; and what the tool may read, change or send. Record “not established” rather than guessing.

The three routes below describe documented workflows checked October 5, 2026—not locally observed product results or a vendor ranking.

Separate drafting workspace: Vero note preparation

Vero’s documentation describes recording, typed context or uploads, selecting a template, creating and editing a note, then copying it into an EMR or exporting PDF, Word, print or email. Those are vendor-documented steps, not an observed test. Copy/export is not a claim of native EHR integration or automatic order execution. Vero’s note instructions.

Vero is relevant when the purchasing problem is reviewed note preparation. This article does not rank it above clinical devices, inbox products or operational systems performing different tasks. A clinic seeking autonomous diagnosis is solving a different problem.

EHR-connected example: Dragon Copilot for physicians

• Offering and inputs: Microsoft’s embedded Dragon Copilot route captures an encounter recording inside an EHR’s mobile or desktop application and generates a clinical summary. This requires a partner-supported implementation; it is not a plug-in for every EHR. Microsoft requires patient consent before encounter recording. Embedded workflow documentation.
• Destination: in that embedded route, the summary arrives in the EHR, where users edit it. In contrast, the standalone Dragon Copilot apps require manual transfer. A standalone subscription does not by itself establish an embedded connection. Embedded versus standalone delivery.
• Availability constraints: Microsoft lists physician access in the U.S. and Canada, among other markets, and embedding in supported EHRs such as Epic. The exact site configuration, enabled features and commercial terms still need confirmation; the embedded route also requires a separate EHR contractual relationship. Role and market availability, EHR relationship requirements.
• Human approval: a qualified, trained care-team user reviews the output; the customer remains responsible for approval and filing in the system of record. Dragon Copilot is not that repository. Microsoft’s intended-use and filing responsibilities.

The local acceptance endpoint is therefore a reviewed note in the correct encounter, not merely a generated summary. Inspect the saved version and any outstanding work; do not infer that a note draft has executed orders.

Clinical-device example: LumineticsCore diabetic-retinopathy testing

• Offering and inputs: Digital Diagnostics’ LumineticsCore, formerly IDx-DR, detects more than mild diabetic retinopathy. Its U.S. indications specify adults aged 22 or older with diabetes and no previous diabetic-retinopathy diagnosis, using the Topcon NW400. A trained operator captures two retinal images per eye and submits them for analysis. Review the full exclusions rather than treating age and diagnosis as sufficient eligibility. Documented capture workflow, U.S. indications and exclusions.
• Destination: FDA record DEN180001 describes image-quality and disease results returning to the device client. The vendor’s SphereDx results platform also documents individual exam-result PDF downloads. An available PDF is not proof of automatic EHR filing or a completed referral. FDA device description, pages 2–3, SphereDx results delivery.
• Availability constraints: this example uses the U.S. labeling and prescription-device record. It does not establish Canadian authorization or a local installation; verify those separately for the exact configuration. FDA prescription-use limitation, page 1.
• Human step: unlike a draft note, the device produces its diagnostic result without a specialist image overread. Its labeling nevertheless calls for physicians to review results and advise patients about referrals. A no-result exam requires retesting or referral, not a negative-status substitution. Autonomous result workflow, Result review and no-result instructions.

The local acceptance endpoint includes the correctly associated result and an owned follow-up pathway. The MASAI mammography findings above are not evidence for this different device, disease or population.

For every route, test the receiving system. A draft export can lose structure; an interface can map an unresolved state to complete; a permission can be wider than the demonstration suggests. The EHR integration guide explains why interface availability is only the beginning of acceptance.

Worked example: AI-assisted referral intake

Case SOL-01 is an original fictional administrative rehearsal. It does not demonstrate any vendor’s performance or clinical prioritization. Its purpose is to define an observable acceptance decision before a clinic buys a tool.

The fictional clinic wants software to extract referral fields and propose a missing-item checklist. Its locally supplied requirement is a signed referral and an associated outside report. Intake staff owns document completeness. Clinical urgency and appointment decisions remain with the qualified clinical team.

Fixed source packet and boundaries

• Referral R-101 identifies fictional person TEST-A and is signed October 2, 2026. It requests an appointment but supplies no urgency classification.
• Intake record I-101, updated October 5 at 09:00, says: “Outside report requested; not received.”
• Attachment X-202 is readable but identifies TEST-B and referral R-202. It is intentionally included to test identity handling, not to provide information for TEST-A.
• The assistant may read the approved packet and stage a checklist. It cannot import X-202 into TEST-A’s record, set clinical priority, send a message or close the referral.

The expected output is: signed referral present; required report missing; unrelated attachment excluded; completeness pending; assigned to the intake coordinator. There is no basis for “routine” urgency, “normal report” or “ready to book.”

Flawed proposal and completed review

The invented proposal reads: “Referral complete. Outside report normal. Routine appointment; close intake task.” Fluent language hides three different defects: the wrong source association, an unsupported clinical finding and an action outside the approved scope.

Show the completed SOL-01 acceptance record

Requirement and evidence

R-101 needs its own outside report. I-101 records that it has not arrived. X-202 belongs to another fictional person and referral.

Observed text in this teaching example

The invented proposal marks the packet complete, calls a report normal and proposes closing work without authority. These are supplied fictional defects, not observations from a product.

Corrected checklist

Signed referral present. Associated report missing. X-202 excluded. No clinical priority assigned. Completeness pending; intake coordinator owns follow-up.

Receiving-workflow check

No unrelated attachment is imported. Referral remains open. The missing-report work item remains assigned. No booking or patient message is sent.

Decision

Hold release of this workflow. Correcting one proposal is not prevention. Repair source association and permitted-action controls, then repeat the test and inspect destination state and audit events.

This example separates a content repair from an implementation decision. A human can correct the sentence, yet the clinic should not accept a configuration that repeatedly attaches another person’s report or silently completes unresolved work.

A repeatable acceptance pack

Run the same base packet with the variations below. Keep inputs and expected states fixed, record the configuration and preserve raw output before editing. These are proposed tests, not completed results. Use only fictional information in this rehearsal; actual patient-data testing requires local approval.

Scroll horizontally to read the supplied change and required evidence for each test.

For an actual test, distinguish pass, fail, not run and not applicable with a reason. A drafting-only tool is not defective because it cannot create EHR tasks; task creation may belong to a separate interface. The complete workflow still needs a named owner and an accepted delivery route.

Worked scheduling example: a forecast is not capacity

Case SOL-02 is a fictional planning exercise, not a measured forecast, scheduling deployment or recommended staffing standard. It concerns already triaged appointment requests; AI is not assigning clinical urgency.

1. Inputs and prediction: for a Tuesday 09:00–10:00 block, an invented model output predicts six requests for the same appointment type. A real forecast would need dated request history—including requests that could not be booked—plus holidays, cancellations and current availability. Appointment counts alone can conceal unmet demand.
2. Hard constraints: the fictional clinic supplies two suitable rooms, two qualified clinicians available for the whole block, and funded support coverage for both rooms. Its local slot rule is 30 minutes, including turnover. Capacity is therefore 2 rooms × 60 minutes ÷ 30 minutes = 4 appointments, not six. No clinician, room or staff member can be double-booked.
3. Proposal and approved action: reject a proposed six-slot schedule. The operations lead approves four slots and assigns the scheduling coordinator to resolve any excess requests using the clinic’s approved routing and communication rules. Extra capacity requires confirmed staffing, room time and budget before approval. The tool may stage a proposal, not publish appointments, message patients or override clinical triage. A staff absence triggers recalculation and human reapproval.
4. Completed paper check: suppose five requests actually arrive in this fictional exercise. Four are scheduled within the block and one remains assigned for resolution. The forecast’s absolute error is |6 − 5| = 1 request. Filling 4/4 slots does not mean all demand was served: one of five requests remains outstanding. No waiting-time or efficiency improvement has been demonstrated.

For a pilot, compare the forecast-assisted decision with the current planner or a simple historical rule over comparable blocks. Retain every request, prediction timestamp, capacity snapshot, approval and subsequent change. Measure forecast error separately from time to appointment, unresolved requests at cutoff, overtime, displaced sessions and staff effort. Report relevant appointment types and sites separately. This distinguishes a better prediction from a useful, feasible scheduling decision—and tests whether AI adds value over ordinary rules.

Implementation gates and the evidence to keep

The following gates are Vero’s editorial implementation aid, not a validated risk score, clinical standard or substitute for organizational approval. NIST’s voluntary AI Risk Management Framework provides a broader foundation for managing AI risk, including its generative-AI profile.

1. Problem gate: record the task, baseline and non-AI comparator. Identify who benefits and who might inherit additional work. Keep the baseline definition and sampling period.
2. Evidence gate: record the exact offering, studied task, endpoint and limitations. Ask whether the evidence matches your population and proposed use. Keep source links, labeling and the vendor’s configuration statement.
3. Data and authority gate: approve source access, destination permissions and data handling before patient use. Keep the data-flow map, contract decision and access test. A convenient demo account is not an organizational authorization.
4. Acceptance gate: run fixed failure cases and a controlled workflow pilot. Agree stop conditions before reviewing results. Keep raw outputs, corrections, destination checks, incidents and reviewer decisions.
5. Monitoring and exit gate: assign ongoing quality review, update handling, fallback and export ownership. Keep the change log, exception trend and an exercised exit record.

Proceed only when the relevant gates are resolved. Do not average a failed identity or authorization control into a reassuring percentage. Conversely, mark genuinely out-of-scope requirements as such instead of demanding every tool perform every function.

Measure the pilot without hiding failure

Choose a sample with the local clinical, operations and evaluation team. Its size should reflect the task and risk; there is no universal encounter count that validates a healthcare AI solution. Track every eligible attempt, including abandoned, failed and manually completed work. Compare similar work and record changes in staffing or volume.

For a purely fictional measurement illustration, 30 eligible referral packets might include 22 accepted after review, four requiring manual reconstruction, two processing failures and two not attempted because source access was unavailable. That is 22/30 accepted after review, not 22/22 perfect performance. “Accepted after review” must not be relabeled as error-free raw output. This illustration is neither a pilot result nor a recommended acceptance threshold.

Report effort by role and error by category: source association, omission, unsupported addition, priority inference, permission, delivery and unresolved ownership. An efficiency improvement that shifts extra work to unfunded staff is not a completed implementation benefit.

Privacy and regulation follow the function and location

United States: FDA device authorization and HIPAA obligations answer different questions. The FDA’s AI-enabled device list links to individual marketing-authorization records and explicitly says it is not comprehensive. Read the exact intended use; absence from the list alone does not establish regulatory status.

For HIPAA-covered organizations, HHS cloud guidance explains that a provider processing or storing electronic protected health information on the organization’s behalf can be a business associate even without the decryption key. Appropriate agreements and the organization’s own risk analysis remain necessary. A “HIPAA-compliant” badge is not the complete assessment.

Canada: Health Canada’s April 2026 pre-market ML-device guidance addresses manufacturers applying for or amending Class II, III and IV device licences. It emphasizes intended use, population, inputs, outputs and clinical validation. It does not make every administrative AI tool a medical device, or replace provincial privacy obligations.

Ontario example: the IPC’s January 2026 AI-scribe checklist generally calls for express consent before use and recording that consent in the health record. It also covers accuracy review, contracts and third-party data sharing. Configure a meaningful explanation, refusal route and manual alternative with the responsible privacy and clinical team. This is Ontario-specific guidance, not a statement of requirements in every province or U.S. state.

Create a requirements register with source rule → local owner → configured control → retained evidence. One example is: Ontario AI-scribe consent guidance → privacy lead → locally approved explanation and recorded consent before capture → approved script version and consent-workflow test. Retain the actual implementation evidence internally; this page contains no patient information.

Human oversight has to be executable

“A human reviews it” is incomplete unless the reviewer can see the supporting information, has time to inspect it, can correct the destination and can stop use. Define absence coverage and an escalation route. A person rubber-stamping output under impossible workload is not an effective control.

WHO’s guidance on large multi-modal models identifies inaccurate output, bias and automation bias among the risks. Our implementation recommendation is to test each intended language and relevant user group separately, with qualified language and clinical reviewers where appropriate. Preserve uncertainty and communication preferences; a fluent translation is not evidence of equivalent meaning.

Cost the complete workflow, not the subscription

Ask for the billing unit and exclusions in writing: clinician seat, user, location, examination, document, API usage or enterprise licence. Include setup, migration or interfaces, equipment, review, exceptions, support, renewals and exit work. Compare the same volume and destination. A lower unit price can be outweighed by additional manual handling.

Consider 500 referral packets per month, using invented assumptions in U.S. dollars—not vendor prices or observed savings:

• Current workflow: six staff minutes at a loaded $45/hour and two clinician minutes at $150/hour per packet. That costs $2,250 + $2,500 = $4,750/month in modeled labor.
• Proposed workflow: four staff minutes, still two clinician minutes, $600/month software, $1,200 setup spread over six months, and $300/month support. Modeled cost is $1,500 + $2,500 + $600 + $200 + $300 = $5,100/month.
• Difference: $350 more per month, despite saving two staff minutes per packet. If staff effort falls to three minutes with the same quality and other assumptions, the total is $4,725, only $25 below baseline.

The model assumes the staff and clinician minutes include corrections, exceptions and failed-attempt recovery across all 500 packets. If not, add that work. Setup allocation is a planning convention, not the payment schedule. Released staff time is capacity, not automatically cash savings; identify what useful work it enables before calling it a return on investment.

Clinical devices may justify investment through a clinical endpoint rather than labor savings. Keep that benefit claim tied to applicable evidence and the authorized workflow instead of forcing every solution into the same time-saving calculation.

A practical buying decision

Choose pilot when the problem is bounded, sources and permissions are available, reviewers are funded and a credible comparator exists. Choose repair first when the main obstacle is missing information, unclear ownership or an unreliable interface. Choose do not deploy yet when a required identity, authorization or recovery control fails.

Keep one decision record: task and scope; exact configuration and date; evidence limitations; accepted and failed checks; total effort by role; unresolved risks; accountable approver; and the condition for reconsideration. That is more useful than a feature count or a universal “best AI” claim.

Sources and further reading

• Randomized outpatient scribe trial, Lukac et al., 2025
• Randomized waiting-list message-drafting study, Tai-Seale et al., 2024
• MASAI mammography screening trial, 2026
• FDA AI-enabled medical device list
• Health Canada pre-market ML-device guidance, April 2026
• HHS HIPAA cloud-computing guidance
• IPC Ontario AI-scribe checklist, January 2026
• WHO large multi-modal model governance guidance, 2024
• NIST AI Risk Management Framework
• Vero note-creation instructions — product documentation
• Microsoft Dragon Copilot embedded and standalone workflows — product documentation
• Microsoft Dragon Copilot role and market availability — vendor documentation
• Microsoft Dragon Copilot intended use and EHR filing responsibilities
• LumineticsCore capture and result workflow — vendor documentation
• LumineticsCore U.S. indications, exclusions and result-review instructions
• FDA IDx-DR De Novo record DEN180001 — original device configuration
• SphereDx results platform and PDF delivery — vendor documentation